DNA damage response proteins and oxygen modulate prostaglandin E2 growth factor release in response to low and high LET ionizing radiation

Frontiers in Oncology

Volumn 5, Issue DEC, 2015, Pages

  Allen, Christopher P ^a   Tinganelli, Walter ^b,c   Sharma, Neelam ^a   Nie, Jingyi ^a   Sicard, Cory ^a   Natale, Francesco ^b   King, Maurice ^a   Keysar, Steven B ^d   Jimeno, Antonio ^d   Furusawa, Yoshiya ^c   Okayasu, Ryuichi ^e   Fujimori, Akira ^e   Durante, Marco ^b   Nickoloff, Jac A ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

^b GSI HELMHOLTZZENTRUM FÜR SCHWERIONENFORSCHUNG GMBH   (Germany)

^c NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^d UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^e NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

Author keywords

Apoptosis; Caspase; DNA damage response; Growth factor; Radiotherapy

Indexed keywords

CASPASE 3; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; INDOMETACIN; PROSTAGLANDIN E2;

APOPTOSIS; ARTICLE; CELL PROLIFERATION ASSAY; CELL SURVIVAL; CELL VIABILITY; CLONOGENIC ASSAY; CONTROLLED STUDY; DNA DAMAGE; ENZYME LINKED IMMUNOSORBENT ASSAY; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; IONIZING RADIATION; IRRADIATION; LIQUID CHROMATOGRAPHY; OXYGEN CONCENTRATION; TANDEM MASS SPECTROMETRY;

EID: 84954130116     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2015.00260     Document Type: Article

References (52)

1. Calderwood SK. Tumor heterogeneity, clonal evolution, and therapy resistance: an opportunity for multitargeting therapy. Discov Med (2013) 15(82):188-94.
2. Huang Q, Li F, Liu X, Li W, Shi W, Liu F-F, et al. Caspase-mediated paracrine signaling from dying cells potently stimulate tumor cell repopulation during cancer radiotherapy. Nat Med (2011) 17:860-6. doi:10.1038/nm.2385.
3. Ng WL, Huang Q, Liu X, Zimmerman M, Li F, Li CY. Molecular mechanisms involved in tumor repopulation after radiotherapy. Transl Cancer Res (2013) 2(5):442-8. doi:10.3978/j.issn.2218-676X.2013.10.03.
4. Zimmerman MA, Huang Q, Li F, Liu X, Li CY. Cell death-stimulated cell proliferation: a tissue regeneration mechanism usurped by tumors during radiotherapy. Semin Radiat Oncol (2013) 23(4):288-95. doi:10.1016/j.semradonc.2013.05.003.
5. Li Z, Zhang Y, Kim WJ, Daaka Y. PGE2 promotes renal carcinoma cell invasion through activated RalA. Oncogene (2013) 32(11):1408-15. doi:10.1038/onc.2012.161.
6. Generali D, Buffa FM, Deb S, Cummings M, Reid LE, Taylor M, et al. COX-2 expression is predictive for early relapse and aromatase inhibitor resistance in patients with ductal carcinoma in situ of the breast, and is a target for treatment. Br J Cancer (2014) 111(1):46-54. doi:10.1038/bjc.2014.236.
7. Kurtova AV, Xiao J, Mo Q, Pazhanisamy S, Krasnow R, Lerner SP, et al. Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance. Nature (2015) 517(7533):209-13. doi:10.1038/nature14034.
8. Stracker TH, Usui T, Petrini JH. Taking the time to make important decisions: the checkpoint effector kinases Chk1 and Chk2 and the DNA damage response. DNA Repair (2009) 8(9):1047-54. doi:10.1016/j.dnarep.2009.04.012.
9. Ciccia A, Elledge SJ. The DNA damage response: making it safe to play with knives. Mol Cell (2010) 40(2):179-204. doi:10.1016/j.molcel.2010.09.019.
10. Reinhardt HC, Yaffe MB. Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2. Curr Opin Cell Biol (2009) 21(2):245-55. doi:10.1016/j.ceb.2009.01.018.
11. Putnam CD, Jaehnig EJ, Kolodner RD. Perspectives on the DNA damage and replication checkpoint responses in Saccharomyces cerevisiae. DNA Repair (2009) 8(9):974-82. doi:10.1016/j.dnarep.2009.04.021.
12. Peng A, Lewellyn AL, Schiemann WP, Maller JL. Repo-man controls a protein phosphatase 1-dependent threshold for DNA damage checkpoint activation. Curr Biol (2010) 20(5):387-96. doi:10.1016/j.cub.2010.01.020.
13. Fernet M, Megnin-Chanet F, Hall J, Favaudon V. Control of the G2/M checkpoints after exposure to low doses of ionising radiation: implications for hyper-radiosensitivity. DNA Repair (2010) 9(1):48-57. doi:10.1016/j.dnarep.2009.10.006.
14. Allen C, Ashley AK, Hromas R, Nickoloff JA. More forks on the road to replication stress recovery. J Mol Cell Biol (2011) 3:4-12. doi:10.1093/jmcb/mjq049.
15. Kastan MB, Lim DS, Kim ST, Yang D. ATM-a key determinant of multiple cellular responses to irradiation. Acta Oncol (2001) 40(6):686-8. doi:10.1080/02841860152619089.
16. Kitagawa R, Bakkenist CJ, McKinnon PJ, Kastan MB. Phosphorylation of SMC1 is a critical downstream event in the ATM-NBS1-BRCA1 pathway. Genes Dev (2004) 18(12):1423-38. doi:10.1101/gad.1200304.
17. Baskaran R, Wood LD, Whitaker LL, Canman CE, Morgan SE, Xu Y, et al. Ataxia telangiectasia mutant protein activates c-Abl tyrosine kinase in response to ionizing radiation. Nature (1997) 387(6632):516-9. doi:10.1038/387516a0.
18. Burma S, Chen BP, Murphy M, Kurimasa A, Chen DJ. ATM phosphorylates histone H2AX in response to DNA double-strand breaks. J Biol Chem (2001) 276(45):42462-7. doi:10.1074/jbc.C100466200.
19. Chen BP, Uematsu N, Kobayashi J, Lerenthal Y, Krempler A, Yajima H, et al. Ataxia telangiectasia mutated (ATM) is essential for DNA-PKcs phosphorylations at the Thr-2609 cluster upon DNA double strand break. J Biol Chem (2007) 282(9):6582-7. doi:10.1074/jbc.M611605200.
20. Shrivastav M, Miller CA, De Haro LP, Durant ST, Chen BP, Chen DJ, et al. DNA-PKcs and ATM co-regulate DNA double-strand break repair. DNA Repair (2009) 8(8):920-9. doi:10.1016/j.dnarep.2009.05.006.
21. Yajima H, Lee K-J, Chen BPC. ATR-dependent DNA-PKcs phosphorylation in response to UV-induced replication stress. Mol Cell Biol (2006) 26:7520-8.
22. Matsuoka S, Ballif BA, Smogorzewska A, McDonald ER III, Hurov KE, Luo J, et al. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science (2007) 316(5828):1160-6. doi:10.1126/science.1140321.
23. Shaheen M, Allen C, Nickoloff JA, Hromas R. Synthetic lethality: exploiting the addiction of cancer to DNA repair. Blood (2011) 117:6074-82. doi:10.1182/blood-2011-01-313734.
24. Kelley MR, Logsdon D, Fishel ML. Targeting DNA repair pathways for cancer treatment: what's new? Future Oncol (2014) 10(7):1215-37. doi:10.2217/fon.14.60.
25. Hosoya N, Miyagawa K. Targeting DNA damage response in cancer therapy. Cancer Sci (2014) 105(4):370-88. doi:10.1111/cas.12366.
26. Basu B, Yap TA, Molife LR, de Bono JS. Targeting the DNA damage response in oncology: past, present and future perspectives. Curr Opin Oncol (2012) 24(3):316-24. doi:10.1097/CCO.0b013e32835280c6.
27. Li F, Huang Q, Chen J, Peng Y, Roop DR, Bedford JS, et al. Apoptotic cells activate the "phoenix rising" pathway to promote wound healing and tissue regeneration. Sci Signal (2010) 3(110):ra13. doi:10.1126/scisignal.2000634.
28. Keysar SB, Astling DP, Andersona RT, Vogler BW, Bowles DW, Morton JJ, et al. A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins. Mol Oncol (2013) 7(4):776-90. doi:10.1016/j.molonc.2013.03.004.
29. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst (1990) 82(13):1107-12. doi:10.1093/jnci/82.13.1107.
30. Hawkey CJ. COX-1 and COX-2 inhibitors. Best Pract Res Clin Gastroenterol (2001) 15(5):801-20. doi:10.1053/bega.2001.0236.
31. Okayasu R, Okada M, Okabe A, Noguchi M, Takakura K, Takahashi S. Repair of DNA damage induced by accelerated heavy ions in mammalian cells proficient and deficient in the non-homologous end-joining pathway. Radiat Res (2006) 165(1):59-67. doi:10.1667/RR3489.1.
32. Hirakawa H, Fujisawa H, Masaoka A, Noguchi M, Hirayama R, Takahashi M, et al. The combination of Hsp90 inhibitor 17AAG and heavy-ion irradiation provides effective tumor control in human lung cancer cells. Cancer Med (2015) 4:426-36. doi:10.1002/cam4.377.
33. Wang H, Wang Y. Heavier ions with a different linear energy transfer spectrum kill more cells due to similar interference with the Ku-dependent DNA repair pathway. Radiat Res (2014) 182(4):458-61. doi:10.1667/RR13857.1.
34. Shieh SY, Ahn J, Tamai K, Taya Y, Prives C. The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes Dev (2000) 14(3):289-300. doi:10.1101/gad.14.3.289.
35. Anderson RT, Keysar SB, Bowles DW, Glogowska MJ, Astling DP, Morton JJ, et al. The dual pathway inhibitor rigosertib is effective in direct patient tumor xenografts of head and neck squamous cell carcinomas. Mol Cancer Ther (2013) 12(10):1994-2005. doi:10.1158/1535-7163.MCT-13-0206.
36. Jimeno A, Weiss GJ, Miller WH, Gettinger S, Eigl BJC, Chang ALS, et al. Phase I study of the hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors. Clin Cancer Res (2013) 19(10):2766-74. doi:10.1158/1078-0432.CCR-12-3654.
37. Keysar SB, Le PN, Anderson RT, Morton JJ, Bowles DW, Paylor JJ, et al. Hedgehog signaling alters reliance on EGF receptor signaling and mediates anti-EGFR therapeutic resistance in head and neck cancer. Cancer Res (2013) 73(11):3381-92. doi:10.1158/0008-5472.CAN-12-4047.
38. Connell PP, Weichselbaum RR. A downside to apoptosis in cancer therapy? Nat Med (2011) 17(7):780-2. doi:10.1038/nm0711-780.
39. Labi V, Erlacher M. How cell death shapes cancer. Cell Death Dis (2015) 6(3):e1675. doi:10.1038/cddis.2015.20.
40. Liu X, He Y, Li F, Huang Q, Kato TA, Hall RP, et al. Caspase-3 promotes genetic instability and carcinogenesis. Mol Cell (2015) 58(2):284-96. doi:10.1016/j.molcel.2015.03.003.
41. Rich T, Allen RL, Wyllie AH. Defying death after DNA damage. Nature (2000) 407(6805):777-83. doi:10.1038/35037717.
42. McCool KW, Miyamoto S. DNA damage-dependent NF-kappaB activation: NEMO turns nuclear signaling inside out. Immunol Rev (2012) 246(1):311-26. doi:10.1111/j.1600-065X.2012.01101.x.
43. Dent P, Yacoub A, Contessa J, Caron R, Amorino G, Valerie K, et al. Stress and radiation-induced activation of multiple intracellular signaling pathways. Radiat Res (2003) 159(3):283-300. doi:10.1667/0033-7587(2003)159[0283:SARIAO]2.0.CO;2.
44. Basu S, Rosenberg KR, Youmell M, Price BD. The DNA-dependent protein kinase participates in the activation of NFkB following DNA damage. Biochem Biophys Res Commun (1998) 247:79-83. doi:10.1006/bbrc.1998.8741.
45. Sabatel H, Pirlot C, Piette J, Habraken Y. Importance of PIKKs in NF-kappaB activation by genotoxic stress. Biochem Pharmacol (2011) 82(10):1371-83. doi:10.1016/j.bcp.2011.07.105.
46. Tsatsanis C, Androulidaki A, Venihaki M, Margioris AN. Signalling networks regulating cyclooxygenase-2. Int J Biochem Cell Biol (2006) 38(10):1654-61. doi:10.1016/j.biocel.2006.03.021.
47. Donato AL, Huang Q, Liu X, Li F, Zimmerman MA, Li CY. Caspase 3 promotes surviving melanoma tumor cell growth after cytotoxic therapy. J Invest Dermatol (2014) 134(6):1686-92. doi:10.1038/jid.2014.18.
48. Zhang Z, Wang M, Zhou L, Feng X, Cheng J, Yu Y, et al. Increased HMGB1 and cleaved caspase-3 stimulate the proliferation of tumor cells and are correlated with the poor prognosis in colorectal cancer. J Exp Clin Cancer Res (2015) 34:51. doi:10.1186/s13046-015-0166-1.
49. Hu Q, Peng J, Liu W, He X, Cui L, Chen X, et al. Elevated cleaved caspase-3 is associated with shortened overall survival in several cancer types. Int J Clin Exp Pathol (2014) 7(8):5057-70.
50. Yang J, Yue JB, Liu J, Sun XD, Hu XD, Sun JJ, et al. Effect of celecoxib on inhibiting tumor repopulation during radiotherapy in human FaDu squamous cell carcinoma. Contemp Oncol (Pozn) (2014) 18(4):260-7. doi:10.5114/wo.2014.43932.
51. Inoue T, Anai S, Onishi S, Miyake M, Tanaka N, Hirayama A, et al. Inhibition of COX-2 expression by topical diclofenac enhanced radiation sensitivity via enhancement of TRAIL in human prostate adenocarcinoma xenograft model. BMC Urol (2013) 13:1. doi:10.1186/1471-2490-13-1.
52. Allen CP, Borak TB, Tsujii H, Nickoloff JA. Heavy charged particle radiobiology: using enhanced biological effectiveness and improved beam focusing to advance cancer therapy. Mutat Res (2011) 711:150-7. doi:10.1016/j.mrfmmm.2011.02.012.